title: Pharmacokinetics in special populations.
abstract: Pharmacokinetics are typically dependent on a variety of physiological variables (e.g., age, ethnicity, or pregnancy) or pathological conditions (e.g., renal and hepatic insufficiency, cardiac dysfunction, obesity, etc.). The influence of some of these conditions has not always been thoroughly assessed in the clinical studies of antiallergic drugs. However, the knowledge of the physiological grounds of the pharmacokinetics can provide some insight for predicting the potential alterations and guiding the initial prescription strategies. It is important to recognize that both pharmacokinetic and pharmacodynamic differences between populations should be considered. The available information on drugs used for the therapy of allergic diseases is reviewed in this chapter.
authors: Clinical Pharmacology/Modeling & Simulation, GlaxoSmithKline, Verona, Italy. italo.2poggesi@gsk.com
authors: Italo
authors: I
authors: Poggesi
authors: Margherita Strolin
authors: MS
authors: Benedetti
authors: Rhys
authors: R
authors: Whomsley
authors: Sophie
authors: S
authors: Le Lamer
authors: Mathieu
authors: M
authors: Molimard
authors: Jean-Baptiste
authors: JB
authors: Watelet
mesh_terms: D000328:Adult; D000367:Age Factors; D000818:Animals; D018926:Anti-Allergic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D006331:Heart Diseases / Q000150:complications / Q000378:metabolism; D048550:Hepatic Insufficiency / Q000150:complications / Q000378:metabolism; D006801:Humans; D006967:Hypersensitivity / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D008658:Inactivation, Metabolic; D009765:Obesity / Q000150:complications / Q000378:metabolism; D051437:Renal Insufficiency / Q000150:complications / Q000378:metabolism
chemical_list: D018926:Anti-Allergic Agents